Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Locations with Cannabis Dispensaries Recorded Fewer Opioid Fatalities, New Research Says

A new study has shown that a significant decline in deaths related to opioids is linked to improved access to cannabis dispensaries. The study, which was reported in the “British Medical Association” journal, concluded that higher counts of recreational and medical dispensary stores were connected with decreased opioid-related mortality rates, particularly deaths linked to synthetic opioids such as fentanyl. The study adds that the discovery holds for both recreational and medical dispensaries.

The researchers examined the prevalence of marijuana dispensaries and opioid death rates in 23 states between the years of 2014 and 2018. The researchers discovered that, in general, counties where the number of legal cannabis shops increased from one to two experienced a 17% decline in fatalities related to opioids. Growth in the number of dispensaries from two to three was associated with an additional 8.5% reduction in opioid deaths.

The study also discovered that the trend was especially strong for deaths linked to synthetic opioids, aside from methadone, with approximately a 21% decline in death rates linked to an increase in the number of dispensaries from one to two.

The researchers wrote that while the reported links aren’t assumed to be causal, they do suggest a possible connection between a decline in opioid-related death rates and an increased prevalence of recreational and medical marijuana dispensaries.

This is not the first study that has found a link between the decreased harms from opioids and legal marijuana access. Various research studies have discovered that cannabis can effectively treat conditions such as chronic pain, with surveys showing that many patients have opted to switch from addictive painkillers, such as opioids, which are commonly prescribed for pain management, to marijuana.

The new study adds that marijuana is considered to be a less-addictive substance as compared to opioids, stating that marijuana has substantial public support and could be used to manage pain.

The study’s findings demonstrate that increasing legal marijuana accessibility is linked to a decline in deaths related to opioids from the T40.4 class, such as fentanyl. This, the researchers say, is particularly important as deaths related to fentanyl are the most common causes of opioid-related deaths.

A separate study, which was conducted earlier this month, has also found that the use of medical marijuana is linked to an increased quality of life and significant declines in the dependence of an individual on prescription drugs, such as opioids.

These studies contain valuable information that could be used by U.S. federal health agencies to learn whether kratom and cannabis, which cause fewer side effects as compared to other prescription drugs, could be used to treat chronic pain.

In related news, RYAH Group Inc. has a popular app called PotBot App, an app that leverages AI to deliver education about medical marijuana. With more than 300,000 downloads under its belts, this app is the most popular in its class within the country.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Could Canna-Tourism Trigger Economic Recovery?

Just as the global economy was finally recovering from the 2007–2008 financial crisis, the coronavirus pandemic struck, effectively plunging the world into the worst recession since World War 2. International travel came to a near-total standstill as countries tried to prevent the virus from entering their borders, disrupting global supply chains. The resultant lockdown and self-distancing orders were devastating for most industries; one of the hardest hit was the hospitality sector, which shouldered millions of lost jobs.

The cannabis industry fared relatively well, on the other hand, with cannabis companies reporting month-over-month sales records even as the pandemic ravaged the economy. In the United States, states with legal cannabis markets such as California collected as much as $2 billion in cannabis tax revenue. A year after the virus first appeared in Wuhan, China, countries are looking to rebound from the 2020 economic slump, and cannabis tourism represents quite a lucrative opportunity.

With several states and countries adopting pro-cannabis policies, people residing in jurisdictions that don’t allow cannabis have been traveling to those that do to purchase and consume cannabis. Dubbed cannabis tourism, the “New York Times” reported that the phenomenon was on the rise in 2019, with travel entrepreneurs organizing cannabis-infused experiences such as bus tours of grow facilities, food classes and painting classes.

Research from the Colorado Tourism Office (“CTO”) and partner Strategic Marketing and Research Insights (“SMARI”) reveals that for 6.5% of the people who traveled to Colorado between 2013 and 2018, cannabis was one of the reasons they visited the state. Additionally, 16% of travelers who visited the state in winter 2018–2019 and 15% of 2018 summer travelers also visited a cannabis dispensary or store. SMARI found that cannabis-motivated visitors tend to have longer trips compared to the average visitor, spending 5.1 nights in the state versus 4.6 nights.

And this type of tourism is not confined to just the U.S.; Thailand is planning Southeast Asia’s first-ever medical cannabis tours in 2021 to attract foreign investment, and Canada is evaluating how to use its flourishing cannabis industry to help revive the economy as well as boost national and international tourism. Countries such as Spain, Germany, Jamaica and Uruguay also offer a variety of cannabis-infused experiences to cannabis tourists.

With businesses offering a wide range of exciting cannabis-inspired experiences coupled with higher-value cannabis products such as vape pens and topical creams, cannabis tourism can provide plenty of revenue for countries, states and cities looking to rebound from the COVID-19 recession.

Away from Canna-tourism, many cannabis companies have taken innovation to a whole new level. A clear illustration is the work being done by CannAssist International Corp. (OTCQB: CNSC) through its fully owned Xceptor Labs, which has introduced CBD tinctures, creams, pet drops and capsules with higher absorption levels into the market.

NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CBDNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) Enters Exclusive Partnership with Leading Race Team Loenbro Motorsports

HempFusion Wellness (TSX: CBD.U), a leader in the health and wellness cannabidiol (“CBD”) industry, has announced an exclusive partnership with Loenbro Motorsports, one of the world’s leading race teams. The collaboration makes HempFusion CBD, a leading brand utilizing the power of whole-food hemp nutrition, and Probulin, one of the fastest growing probiotic brands in the U.S. according to SPINs reported data, the exclusive sponsors in their respective categories for the 2021 racing season. The sponsorship kicks off with debut of the HempFusion #00eh car at the 50th Annual DIRTcar Nationals at Volusia Speedway near Daytona, with Loenbro Motorsports’ legendary driver, Steve Arpin, behind the wheel. “Thanks to Loenbro Motorsports’ founders, Paul and Jon Leach, for this exciting partnership providing HempFusion and Probulin many incredible opportunities to engage and educate millions of dedicated race fans across the country in the health and wellness benefits of both CBD and probiotics,” said Ian deQueiroz, HempFusion’s chief of brand strategy. “We couldn’t ask for a better partner than Steve. He’s a true, humble champion who’s always prioritized the fans, making him one of the most popular drivers in the racing community.”

To view the full press release, visit https://cnw.fm/vPUOO

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 U.S. states and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs including tinctures, proprietary FDA Drug-listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on R&D, HempFusion has an additional 30 products under development. HempFusion is a board member of the U.S. Hemp Roundtable and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in-store or by visiting HempFusion online at www.Hempfusion.com or www.Probulin.com.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://cnw.fm/HempFusion

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

420 with CNW — Study Shows Medical Marijuana Beneficial to Parkinson’s Patients

The health and medical field is seeing an increased interest in the use of medical marijuana to reduce symptoms of various ailments such as Parkinson’s disease, now that the herb has been legalized in many regions across the globe.

Results from a survey of Parkinson’s disease patients from Germany show that more than 8% of patients with the disease admitted to using marijuana products and more than half of those users, who made up roughly 54%, revealed that the products had been clinically beneficial.

Marijuana products that contain THC, which is the primary psychoactive compound in marijuana, are allowed to be prescribed in Germany when marijuana can help alleviate disabling symptoms and when prior therapies have not been tolerated by the patient or have been unsuccessful.

On the other hand, products containing pure cannabidiol (“CBD”), which is extracted from the hemp plant directly, are available on the internet as well as in pharmacies, and can be acquired without a prescription.

The researchers’ objective was to evaluate patients’s perceptions of medical marijuana while also assessing the experiences of patients who had already used marijuana products. They carried out a cross-sectional countrywide questionnaire-based survey among German Parkinson’s association members.

The association, Deutsche Parkinson Vereinigung, is the largest group of Parkinson’s disease patients, made up of about 21,000 members from German-speaking nations. The questionnaires were distributed in April 2019, both in the investigator’s clinic and with the group’s membership journal.

The researchers analyzed more than 1,300 questionnaires, with their results showing that the interest in medical marijuana in the Parkinson’s disease community was high. However, knowledge on different types of marijuana products was scanty. From the study population, only 9% of the respondents could differentiate between CBD and THC, 28% were informed on the different routes of administration, i.e., oral administration vs. inhaling, and 51% knew of medical marijuana’s legality.

The researchers found that tolerability was good, with 40% of the marijuana product users reporting that they helped alleviate muscle cramps and pain. Additionally, more than 20% of the users revealed a decrease in restless legs, anxiety, depression, tremors, freezing and a decline of stiffness.

Besides this, patients also reported that as compared to oral products which contained CBD, inhaled marijuana products that contained THC were more effective in remedying stiffness. However, those products were not well tolerated.

Dr. Carsten Buhmann, who was involved in the study, explained that the study’s findings confirmed that patients with Parkinson’s disease had a growing interest in treatment with medical marijuana but had limited knowledge on how to take it and how to differentiate between CBD and THC.

Buhmann then remarked that physicians should consider these angles when giving advice to their patients on treatment with medical marijuana. The findings, he said, may assist physicians in deciding on the type of cannabinoid a patient may benefit from, whether a patient could benefit from the treatment, the symptoms it may address as well as the suitable course of administration.

It should be remembered that cannabis medicines come in different forms, and extracts are fast becoming the go-to favorite among those forms. In Canada, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) is the undisputed leader in the extracts segment, which is estimated to have an annual value of $2.7 billion.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://cnw.fm/PULL

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Utah Begins Medical Marijuana Home Deliveries

When the coronavirus pandemic struck, the cannabis industry was left in a precarious position. Although most states that have legal cannabis markets declared the young industry essential, medical cannabis patients were at great risk every time they headed out to get their medicine. Plenty of them are either elderly, immunocompromised, or both, putting them at an even greater risk of infection and suffering severe symptoms. To help keep both patients and staff safe, some states began allowing cannabis home deliveries.

In Utah, medical marijuana couriers have started making deliveries of medical cannabis orders to patients’ homes. The state first allowed medical dispensaries to make home deliveries last May, as long as the dispensaries met strict requirements for delivering themselves or through a licensed medical marijuana courier. More than 10,000 Utah residents have applied for and received medical cannabis cards and, for plenty of them, going out to buy medical marijuana can be a matter of life and death.

WholesomeCo, a medical cannabis company based in Bountiful, Utah, is starting out small. The company has hired 10 couriers to cover Salt Lake, Tooele, Weber, Cache, Summit, Wasatch and Utah counties. According to CEO Chris Jeffery, the company’s goal is to start making statewide deliveries within six months to give patients who are medically fragile or have long distances to travel in order to access a dispensary a better option of getting their medicine.

The dispensary deals with patients who suffer from multiple sclerosis (“MS”), are terminally ill or suffer with conditions that make it nearly impossible for them to even get out of their bed. Such patients need to have medical cannabis delivered to them as they essentially cannot leave their homes. One Salt Lake patient says she is at such a high risk of contracting COVID-19 due to her health conditions that she hasn’t been to the grocery store since last April.

Jordan Bartholomew, another medical cannabis patient living in Salt Lake City’s Ballpark neighborhood, says he largely gets around using a bicycle. With that mode of transportation, visiting a cannabis dispensary to get medical marijuana for his chronic back pain can be quite challenging. Home deliveries have made things a “lot more comfortable,” stated Bartholomew.

Although Utah allowed cannabis home deliveries last year, WholesomeCo is the first medical dispensary to take advantage of the home-delivery framework. However, officials expect other cannabis companies to follow suit, with the director of the state health department’s Center for Medical Cannabis saying he hopes that couriers will make it easier for rural residents who live hours from cannabis dispensaries to access medical cannabis.

Still on the topic of medical cannabis, a number of companies have established themselves as clear leaders in manufacturing cannabis products geared at the medical marijuana market. A vivid example is Green Hygienics Holdings Inc. (OTCQB: GRYN), which has specialized in producing pharmaceutical-grade industrial hemp products and cannabinoids.

NOTE TO INVESTORS: The latest news and updates relating to Green Hygienics Holdings Inc. (OTCQB: GRYN) are available in the company’s newsroom at http://cnw.fm/GRYN

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Grapefruit USA Inc.’s (GPFT) Time Release THC+CBD Delivery Cream Available on Weedmaps Retail Website

Grapefruit USA (OTCQB: GPFT), a premiere fully licensed California-based cannabis company, has announced that its patented Hourglass(TM) time-release THC+cannabinoid delivery cream is now available in California through Weedmaps’ retail online platform. GPFT’s disruptive Hourglass product features a patented technology that overcomes the challenge of efficient skin absorption of THC and other cannabinoids. The topical cannabis delivery cream enables users to see positive results of a predictable delivery of THC/cannabinoids over time. “The approval of Grapefruit on the Weedmaps’ cannabis product platform represents a milestone for our company because it affirms Hourglass’ efficacy and makes it simple for our clientele to locate and therefore purchase Hourglass at retailers throughout California,” said Grapefruit CEO Bradley Yourist in the press release. “Our customers can simply go online to both locate brick and mortar stores that inventory and sell Hourglass, or order it online and have it delivered directly to their home or office in California via licensed retailers. Another step forward in the dawning of the age of Hourglass. We anticipate that our new Weedmaps listing will not only attract many new retail customers for Hourglass and other Grapefruit products, but will also expose the ‘Grapefruit’ corporate name, and Grapefruit’s trademarked ‘Hourglass’ name on our OTCMarkets ticker symbol ‘GPFT’ to a new, massive national and international cannabis-centric audience which is constantly seeking innovative technology based products such as Hourglass in the cannabis space.”

To view the full press release, visit https://cnw.fm/RrZRU

About Grapefruit USA Inc.

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. To find out more about the company, please visit www.GrapefruitBlvd.com.

NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://cnw.fm/GPFT

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Minnesota Governor Asks Legislators to Consider Cannabis Legalization

Governor Tim Waltz of Minnesota urged state legislators earlier this week to consider legalizing marijuana so that racial justice can be attained in addition to boosting the economy.

He made those comments during a briefing at which he was talking about his 2022–2023 budget proposals. During that briefing, the governor was asked if he is willing to authorize sports betting as a way of boosting tax collection in the state.

In his reply, Gov. Waltz said that while he wasn’t opposed to sports betting, his attention was more centered on cannabis legalization since the taxes collected from a regulated marijuana market had the potential to dwarf those which sports betting might yield.  Furthermore, he said that cannabis legalization would go a long way toward addressing matters of equity and racial justice within the state.

The governor continued his remarks on this issue by revealing that he was well aware that neighboring states had legalized sports betting as well as cannabis, and so he wasn’t removing any of those options from the table although cannabis legalization was a bigger priority to him.

Waltz added that he was aware that both options had their potential problems, incluiding the cost to the people, but he was still open to allowing legalization on either matter to proceed.

However, while some governors of other states did include cannabis legalization in their budget requests, Waltz opted not to include this request in his current budget.

Nevertheless, in 2019 the governor had instructed state agencies to get ready for implementing reforms to the marijuana policies of the state. This was as a result of the governor’s anticipation that cannabis legalization would be enacted.

At the start of this month, the State Assembly majority leader indicated that when the new session of the House begins, he will table a proposal to legalize recreational marijuana. He added that if the Republicans within the state Senate block the legalization, he hoped that they would at least be willing to let the matter be put before voters in 2022 through a ballot measure.

Melissa Hortman (D), the speaker of the House, also believes that Republicans in the Senate were the biggest stumbling block to the state making progress on marijuana legalization. She added that establishing a framework through which a cannabis market can be established within the state provides a better way to address the harms of marijuana while improving the criminal justice and health-care systems.

Meanwhile, Paul Gazelka (R), the Senate majority leader, says that he is willing to look at proposals to address matters of equity and expanding the medical marijuana program of Minnesota. However, he added, he isn’t open to considering cannabis legalization because such a move, in his view, isn’t appropriate for Minnesota.

It remains to be seen whether the recent success of a ballot measure in neighboring South Dakota, as well as the push by Gov. Tony Evers of Wisconsin to legalize marijuana, will have a knock-on effect in Minnesota.

Meanwhile, marijuana companies are thriving in states such as Michigan where legal cannabis programs are underway. A vivid example is that of Gage Cannabis Co., a firm that already has more than one dozen retail outlets and many more slated to be opened this year in addition to the company going public on a Canadian exchange within the first quarter of 2021.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis Co. are available in the company’s newsroom at https://cnw.fm/GAGE

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — French Cannabis Legalization Consultation Gathers More Than 200,000 Responses

A survey on marijuana legalization that was launched on Jan. 13, 2021, has already amassed 200,354 responses. The numbers from the survey will be used to validate the content of a marijuana adult-use report that the French Parliament is currently developing before introducing various legalization measures.

Augur Associates CEO Benjamin-Alexandre Jeanroy stated that President Macron’s Party was leading the survey, which would make it easy for it to be included in the 2022 presidential program.

The questionnaire was set in motion by 33 members of parliament. One of the members of the National Assembly and Macron’s political party, Caroline Janvier stated in an interview that they were confident about the survey’s success, adding that their primary objective regarding marijuana was to succeed in changing the debate’s terms. She then mentioned that many politicians did not think of it as a big issue.

Janvier explained that the survey would help confirm the party’s intuition: that the expectations of the general public on regulating and legalizing recreational marijuana went further than the expectations of politicians.

The questionnaire has various questions, with the main one asking respondents whether they are of the opinion that the system that is currently in place is effective in its fight against the illicit use of marijuana and its trafficking.

Other questions focus on legalization models and decriminalization. In addition to these, there were also questions on risk perception included in the questionnaire. Here, respondents are asked to compare the risks of tobacco and alcohol with those of marijuana. The consultation will be open until Feb. 28.

Additionally, Janvier revealed that France spent roughly 600 million euros annually on the fight against marijuana trafficking, adding that according to a confidential police report, marijuana trafficking had risen by 300% since the year 2000.

Furthermore, the number of marijuana consumers had grown, with about half of the country’s population having tried to smoke marijuana at least once in their lives. She noted that marijuana was broadly consumed across the country, which had the largest number of consumers in the European Union.

Janvier observed that marijuana legalization could add roughly 2 billion euros to the country’s coffers.

A survey conducted recently by Le Parisien questioned a few dozen French mayors in the Paris region, which is the most densely populated of the 18 regions in France. The survey found that while only 22% of the population opposed marijuana legalization, half of the mayors in the region surveyed were in favor of the herb being legalized.

Closer to home, in the United States, the booming cannabis industry has created room for massive levels of innovations to be introduced. For instance, The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) has registered record-breaking growth in sales year-on-year, partly driven by its CBD-infused edible and topical products.

NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Top Mistakes Made While Using CBD to Combat Anxiety

Over the past couple of years, cannabidiol (“CBD”) has seen exponential growth in popularity. One of more than 100 cannabinoids produced by the hemp plant, CBD has potent and versatile medicinal properties. Preliminary research and anecdotal evidence have found the hemp extract to be effective at treating issues from anxiety and depression to insomnia and chronic pain. According to Gallup, 20% of Americans who use CBD do so to relieve anxiety.

However, not everyone who uses CBD to combat anxiety achieves the desired effects. Cannabidiol tends to react with each individual differently based on factors such as age, dosage and, body composition, although ultimately, the effects are more or less the same. However, there are a few common user mistakes to be aware of that could make CBD ineffective.

Using low-quality CBD products. Despite CBD’s immense popularity, the cannabidiol industry is quite new and lacks a comprehensive regulatory framework. The result is what has been called a Wild West industry teeming with plenty of unscrupulous sellers who are willing to do and say whatever it takes to make a buck. These bad players have flooded the market with CBD products that are either contaminated with residual solvents, pesticides, heavy metals or THC, or that have barely any actual CBD in them.

Such products are not only ineffective, but they can also cause users to fail drug tests or, even worse, experience health issues. Consumers can take some measures to ensure the CBD they buy is of high quality and can help alleviate their anxiety. Before users purchase a product, they should inspect its certificate of analysis (“COA”). The COA will detail the CBD product’s entire cannabinoid and terpene profile, along with any presence of heavy metals, pesticides, solvent residues and mycotoxins.

Using incorrect dosing. Once a high-quality product has been purchased, consumers should avoid incorrect dosing. Given the state of the cannabis industry, CBD doesn’t have consistent industry dosing recommendations. While the risk for overdosing CBD is quite low, using too little will make it ineffective. Since cannabinoids such as CBD and THC interact with everyone uniquely, users will have to work out which dosage works best for them by experimenting at different levels. Potential consumers should talk to their heart-care providers if they are considering trying to treat their anxiety or other symptoms with CBD, especially if they are pregnant or taking other medication.

Most experts recommend starting with a small dose, perhaps 20 to 40 mg a week. If the effects don’t kick in after a week, consumers can gradually increase the dose by 5 mg every seven days until symptoms start decreasing.

While on the subject of dosage, RYAH Group Inc. offers an excellent interactive platform called RYAH MD on which patients can interact with doctors remotely, while doctors can use that platform to set the dosage for patients.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Massachusetts Cannabis Firms’ Association Drops Lawsuit Challenging Cannabis Delivery Regulations

A business group that represents many of the cannabis shops in the state of Massachusetts had announced that it will be dropping the legal challenge it filed to block new marijuana industry regulations that allowed home delivery.

The Commonwealth Dispensary Association (“CDA”) declared in its suit that the Cannabis Control Commission’s (“CCC”) new delivery-only licenses infringed on the cannabis laws of the state, which already gave retailers the right to deliver marijuana under their current licenses.

In a statement the CDA had filed earlier this month, the association stated that the CCC had gone against its authority and ignored the laws of the state by completely overturning already-established rules that many small businesses had been observing in their operations since 2016.

The “Boston Globe” reported that in the days following the suit, New England Treatment Access, which is among the biggest cannabis firms in the state with shops in Brookline and Northampton, left the CDA. Cultivate, another firm that has shops in Framingham and Leicester, and an estimated 10 additoinal firms also left the dispensary association.

The new regulations introduced by the CCC created two types of delivery licenses:

  • A cannabis courier license, which allows one to charge fees to make deliveries from dispensaries and retailers that are licensed by the CCC
  • A cannabis delivery operator license, which allows one to purchase products wholesale from manufacturers and growers and sell them to their own consumers

Advocates insist that these licenses will level the playing field between small businesses and big corporations, as the barriers for obtaining a delivery license are not as demanding as those that govern obtaining a retail license.

After dropping its suit, the CDA promised to work with groups such as Massachusetts Cannabis Association for Delivery (“MCAD”) to achieve mutual goals, such as increasing the participation of different entrepreneurs in the cannabis industry.

MCAD president Christopher Fevry stated that his association was pleased to know that the CDA had dropped the filed charges but added that it would still not be enough; he noted that well-capitalized and established firms need to be willing to take concrete steps towards ensuring the marijuana industry in Massachusetts is not only fair but also equitable.

On the other hand, the Cannabis Business Association (“CBA”), which had backed the delivery regulations introduced by the CCC, stated that it was glad to see the CDA drop its suit, mentioning that it would continue working with regulators and advocates to address various disparities in the state’s marijuana industry.

Meanwhile, California-based CannAssist International Corp. (OTCQB: CNSC) offers a proprietary technology (CiBiDinol) and exclusive products made using that technology that have undergone independent lab testing which has confirmed that they are 400% better able to penetrate the skin in comparison to conventionally made topical products.

NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.